Cost-effectiveness and budget-impact analysis of Acetazolamide in decompensated heart failure patients with volume overload in the German health care system
Acetazolamide appears to be a cost-effective and potentially cost-saving adjunct to standard care in patients hospitalized with ADHF in Germany. Broad adoption of acetazolamide could reduce inpatient costs for ADHF, with potential annual savings ranging from tens to hundreds of millions of euros depending on eligibility and uptake.
Authors
- Lutz Frankenstein (ORCID: https://orcid.org/0000-0001-7216-1004)
- Norbert Frey (ORCID: https://orcid.org/0000-0001-7611-378X)
- Bent Estler (ORCID: https://orcid.org/0000-0002-2043-4557)
- Tobias Täger
- Hanna Fröhlich (ORCID: https://orcid.org/0000-0002-6355-476X)
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
Publication Details
- Journal
- European Heart Journal - Quality of Care and Clinical Outcomes
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1093/ehjqcco/qcaf140
- Citations
- 1
- Primary Topic
- Renal function and acid-base balance
- Type
- article
- Field-Weighted Citation Impact
- 1.43